Company profile: Haystack Oncology
1.1 - Company Overview
Company description
- Provider of tumor-informed liquid biopsy and ctDNA detection solutions to diagnose minimum residual disease and inform therapy decisions, including Haystack MRD to detect residual/recurrent/resistant disease; Haystack Duo Chemistry for sensitive detection of low-abundance mutant DNA; and clinical trial collaborations to evaluate therapeutic response.
Products and services
- Haystack MRD: A tumor-informed liquid biopsy test that detects circulating tumor DNA (ctDNA) to identify residual, recurrent, or resistant disease and enhance MRD diagnosis
- Clinical Trial Collaborations: Trial-integrated partnerships with biopharmaceutical companies and research organizations employing Haystack MRD in clinical studies to evaluate therapeutic response
- Haystack Duo Chemistry: Proprietary sequencing chemistry engineered to detect low-abundance mutant DNA molecules, increasing ctDNA detection sensitivity to enhance MRD diagnosis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Haystack Oncology
Quantum Surgical
HQ: France
Website
- Description: Provider of robotic-assisted interventional oncology solutions for minimally invasive liver cancer treatment, including Epione for planning, targeting, delivery and confirmation of tumor ablation; CT/MRI fusion-based multimodal planning; real-time respiratory monitoring; post-ablation margin verification; and robotic guidance with navigation and haptics (6 DOF) for precise targeting and safe needle release.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quantum Surgical company profile →
Pyxis Oncology
HQ: United States
Website
- Description: Provider of antibody therapeutics intended to promote the body's immune response to cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pyxis Oncology company profile →
Forty Seven
HQ: United States
Website
- Description: Provider of clinical-stage immuno-oncology therapies targeting cancer immune evasion pathways, based on technology licensed from Stanford University. Lead program 5F9 is a monoclonal antibody against the CD47 receptor, a 'don't eat me' signal that cancer cells commandeer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Forty Seven company profile →
Boston Biomedical
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on novel therapeutics to treat cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Boston Biomedical company profile →
Angle
HQ: United Kingdom
Website
- Description: Provider of liquid biopsy cancer diagnostic products for the capture and harvest of circulating tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Angle company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Haystack Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Haystack Oncology
2.2 - Growth funds investing in similar companies to Haystack Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Haystack Oncology
4.2 - Public trading comparable groups for Haystack Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →